Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies. 

Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.

Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.

Though lung cancer looks promising a partner is now needed.

The company’s AN9025 will shortly enter phase 1.

With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.

But the group still hopes to get IGV-001 approved based on overall survival data.

A more comprehensive dataset on JANX007 sends the group’s stock down.